Myelofibrosis involves driver mutations causing JAK-STAT pathway activation, leading to uncontrolled cell growth and various symptoms. JAK inhibitors like Rituxan, Inrebic, Vonjo, and Ojjaara target ...
The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis. Patients with primary or secondary myelofibrosis who developed new or ...
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...
(a)-(d): The bone marrow biopsy shows mild hypercellularity (a, H&E 200×) and mild to moderate fibrosis (b, Reticulin stain, 200×). CD79a (c, 200×) and CD3 (d, 200×) immunostains highlight lymphoid ...
Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise. "I suspect that the incidence is actually higher than what we originally thought, not only ...
About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...
Turkey, March 30, 2026 — Liv Hospital has announced the launch of its enhanced STEM CELL Treatment and Procedures program, designed to improve outcomes for patients diagnosed with myelofibrosis and ...
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
The introduction of momelotinib to treat myelofibrosis with anemia can result in small savings due to reduced transfusion-related costs, according to a budget impact model. Although momelotinib to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results